Drug profile · INN
desvenlafaxine
APO-DESVENLAFAXINE MR
desvenlafaxine (APO-DESVENLAFAXINE MR) is a norepinephrine transporter inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — desvenlafaxine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
desvenlafaxine (APO-DESVENLAFAXINE MR) is a norepinephrine transporter inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Norepinephrine transporter inhibitor
Primary target: Sodium-dependent noradrenaline transporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is desvenlafaxine?
desvenlafaxine (APO-DESVENLAFAXINE MR) is a norepinephrine transporter inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for desvenlafaxine?
APO-DESVENLAFAXINE MR is a marketed brand name for desvenlafaxine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of desvenlafaxine?
desvenlafaxine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.